Apo-Care Pharma
ApoCare Pharma GmbH is a German specialty pharmaceutical company (founded 1993, Bielefeld) that manufactures EMA-approved pediatric liquid formulations in oncology, hematology, and rare diseases, distributes AEDs under the ResQ-Care brand, and serves German pharmacies and oncology-specialized physicians via wholesale and direct sales.
- Company typePrivate
- Founded1993
- HeadquartersBielefeld, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Apo-Care Pharma does
ApoCare Pharma GmbH is a privately held German pharmaceutical company founded in 1993 in Bielefeld, operating as both a specialized medical wholesaler and a manufacturer of proprietary generic and orphan-designated pharmaceuticals. The company focuses on oncology, hematology, immunology, neurology, and rare pediatric diseases, with a portfolio centered on child-friendly liquid oral formulations that enable precise age- and weight-specific dosing. Proprietary products include Xaluprine® (mercaptopurine, EMA orphan drug status 2012), Xromi® (hydroxycarbamide for sickle cell disease from 9 months), Qaialdo® (spironolactone, first liquid dosage form), Jayempi® (azathioprine), PHEBURANE® (urea cycle disorders), and GMP-compliant synthetic Cannabidiol (CBD) for pharmacy compounding. The company also distributes automated external defibrillators under the ResQ-Care brand via an exclusive partnership with CU Medical Systems Inc. established in 2007, and offers a range of medical devices including the HemoType SC point-of-care diagnostic, Nemos transcutaneous stimulator, Emfit epilepsy alarm, and Plaze SAFE air disinfection device.
ApoCare operates a GMP-certified production facility in Heidelberg established in 2012, which supports manufacturing of active pharmaceutical ingredients including Chlorin e6 used in photodynamic therapy research, with a Phase IIb clinical trial completed in 2014 in collaboration with leading German and international research institutions. Revenue is generated through direct sales of proprietary products and exclusive medical device distribution to pharmacies and oncology-specialized physicians across Germany, with distribution structured around GDP-compliant medical wholesale and a direct sales motion targeting oncologists and hematologists. The company is privately held with no disclosed external investors and employs 11-50 people. Pricing is not publicly disclosed.
The business operates exclusively in Germany and targets four primary customer segments: modern pharmacies requiring customized supply of high-priced specialty medicines, oncology-specialized physicians, pediatric patients with rare diseases, and emergency response organizations requiring AEDs. Go-to-market relies on a sales-led approach supplemented by trade fair and scientific conference participation, including the Fetal Cardiology Teaching Course and Hematology conferences. The company has no publicly disclosed revenue, funding rounds, or institutional investment, having grown organically over more than 30 years through product development and selective portfolio expansion.
Apo-Care Pharma firmographics
Firmographics- Name
- Apo-Care Pharma
- Legal name
- APOCARE Pharma GmbH
- Website
- https://apocarepharma.de
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ApoCare Pharma GmbH is a German specialty pharmaceutical company (founded 1993, Bielefeld) that manufactures EMA-approved pediatric liquid formulations in oncology, hematology, and rare diseases, distributes AEDs under the ResQ-Care brand, and serves German pharmacies and oncology-specialized physicians via wholesale and direct sales.
- Ownership category
- akta.pro rank
Apo-Care Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industries
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)
Keywords
Where Apo-Care Pharma is headquartered
LocationHeadquarters
- HQ city
- Bielefeld
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Apo-Care Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Specialty Pharmaceutical Product Sales: Sale of proprietary and distributed pharmaceutical products in oncology, hematology, immunology, and neurology. Products include specialized liquid formulations for pediatric patients (Xaluprine®, Xromi®, Qaialdo®, Jayempi®), GMP active ingredients (CBD), and medical devices. Revenue generated through direct sales to pharmacies and oncology-specialized physicians.
- Medical Wholesale Distribution: Specialized wholesaler supplying pharmacies with high-priced oncology and immunology medicines. Cost optimization and quality-oriented supply chain for modern pharmacy needs. Operates under GDP (Good Distribution Practice) compliance.
- Medical Device Distribution (AEDs): Exclusive distribution of automated external defibrillators (AEDs) and defibrillators from CU Medical Systems Inc. in Germany since 2007 under the ResQ-Care brand.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Apo-Care Pharma product offering
Product offeringCore offering
Apo-Care Pharma GmbH manufactures and distributes specialty generic pharmaceuticals and medical devices in Germany. Its core offering is child-friendly liquid oral suspension formulations for oncology, hematology, immunology, and rare diseases (e.g., Xaluprine®, Xromi®, Qaialdo®, Jayempi®), supported by a GMP-certified production facility in Heidelberg. The company also distributes automated external defibrillators (AEDs) under the ResQ-Care brand as an exclusive partner of CU Medical Systems Inc.
Product overview
ApoCare Pharma GmbH is a pharmaceutical company specializing in oncology, hematology, neurology, and pediatric medicines with over 20 years of experience since its founding in 1993. The company's product portfolio centers on liquid suspension formulations for children, including Qaialdo® (spironolactone), Xaluprine® (mercaptopurine for ALL), Jayempi® (azathioprine), and Xromi® (hydroxycarbamide for sickle cell disease). The company also offers GMP-compliant synthetic Cannabidiol (CBD), PHEBURANE® for urea cycle disorders, and medical devices including AEDs under the ResQ-Care brand, HemoType SC diagnostics, Nemos stimulation devices, Emfit epilepsy alarms, and Plaze SAFE air disinfection units. ApoCare operates a GMP-certified production facility in Heidelberg and focuses on photodynamic therapy research.
Differentiator
Problem solved
Functional benefit
Brands
- ResQ-Care: Brand dedicated to combating sudden cardiac death through distribution of automated external defibrillators (AEDs) and defibrillators from CU Medical Systems Inc. since 2007
Products and services
- Qaialdo® (Spironolactone 10 mg/ml oral suspension) First liquid dosage form of the aldosterone antagonist spironolactone, EMA-approved for precise pediatric dosing from infancy onwards.
- Xaluprine® (Mercaptopurine 20 mg/ml oral suspension) Liquid mercaptopurine formulation for treatment of acute lymphoblastic leukemia (ALL) in children; granted EMA orphan drug status.
- Jayempi® (Azathioprine 10 mg/ml oral suspension) Oral suspension of azathioprine enabling precise pediatric dosing for immunomodulatory therapy, especially for children with swallowing difficulties.
- Xromi® (Hydroxycarbamide oral solution) First hydroxycarbamide therapy approved for children from 9 months of age for sickle cell disease; child-friendly liquid dosage form.
- Cannabidiol (CBD) GMP-compliant synthetically produced CBD for individual patient care, pharmacy dispensing and compounding under German Pharmacy Operating Regulations.
- PHEBURANE® Oral solution for treatment of urea cycle disorders.
- Automated External Defibrillators (AED) - ResQ-Care Automated external defibrillators and defibrillators from CU Medical Systems Inc., distributed exclusively in Germany under the ResQ-Care brand since 2007 for emergency cardiac arrest response.
- HemoType SC Point-of-care diagnostic for sickle cell disease detection.
- Nemos Transcutaneous stimulation device.
- Emfit Epilepsy alarm device for patient monitoring.
- Plaze SAFE HPA-130W Air disinfection device for healthcare environments.
Quantifiable outcome
- Xaluprine® received orphan drug status from EMA in 2012 for acute lymphoblastic leukemia in children
- +2 more outcomes
Companies that use Apo-Care Pharma
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Apo-Care Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Apo-Care Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- CU Medical Systems Inc.coreExclusive distribution partnership for automated external defibrillators (AEDs) and defibrillators from CU Medical Systems Inc. in Germany since 2007. Products are distributed under the ResQ-Care brand (resq-care.de) targeting cardiac arrest emergency response.
- Leading Pharmaceutical Industry Players and Renowned Original ManufacturerscoreClose collaboration with leading pharmaceutical industry players and renowned original manufacturers to provide pharmacies and oncology-specialized physicians with access to a growing portfolio of high-quality oncology generics.
- Leading German and International Research InstitutionscorePartnership with leading German and international research institutions for oncology R&D. Notable work includes pioneering photodynamic therapy (PDT) development with Chlorin e6. Cooperation began in 2003 and led to Phase IIb clinical trial in 2014.
- Medical Experts, Patient Organizations, and Global PartnersminorClose cooperation with medical experts, patient organizations, and global partners to make innovative therapies available in Germany for rare diseases. Focus on development of medicines tailored to specific needs and challenges of rare diseases.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Apo-Care Pharma competitors and assessment
Company assessmentDirect peers
- STADA Arzneimittel AG: German-headquartered specialty and generics pharmaceutical company with a comparable mix of branded specialty products and generic distribution. Apo-Care operates in the same German pharma market and serves similar pharmacy customers, though STADA operates at significantly greater scale.
- Hexal AG (Sandoz): German generics manufacturer and distributor (part of Sandoz/Novartis) supplying generic oncology and other hospital/institutional products to German pharmacies. Highly comparable in product category and customer base to Apo-Care's wholesale generics side.
- Proveca Pharma: UK-based specialty pharmaceutical company focused on pediatric medicines for chronic and rare conditions. Closely comparable niche focus on pediatric specialty formulations, including approvals for conditions Apo-Care also targets.
- Mindray: Global medical device manufacturer with AED and defibrillator products that compete in the same emergency-response equipment space as CU Medical Systems and Apo-Care's ResQ-Care distribution.
- Ethypharm: French specialty generics pharmaceutical company with strong presence in pediatric and hospital specialty products across Europe. Comparable in terms of specialty-generics positioning and pediatric pipeline focus.
- Phoenix Group: Europe's largest pharmaceutical wholesale distributor, headquartered in Germany. Directly comparable wholesale-distribution business model and German pharmacy customer base, though at substantially greater scale.
- SERB Pharmaceuticals: European specialty pharmaceutical company focused on rare diseases and critical care, including PHEBURANE, a urea cycle disorder treatment that Apo-Care distributes in Germany. Direct overlap on rare-disease specialty pharma and orphan-style products.
- ZOLL Medical Corporation: US-based AED and defibrillator manufacturer (part of Asahi Kasei) — a direct competitor to Apo-Care's AED distribution business and the underlying supplier CU Medical Systems Inc.
- ratiopharm GmbH: German generics pharmaceutical company (part of Teva) distributing generic medicines to German pharmacies. Operates in the same generics-and-pharmacy channel as Apo-Care.
Broad incumbents
- Philips (HeartStart): Producer of the HeartStart line of AEDs, a direct competitor in the German AED market where Apo-Care distributes CU Medical units. Philips operates as a much broader medical device incumbent rather than as a niche specialist.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Apo-Care Pharma social profiles
Digital presenceApo-Care Pharma compliance and trust
Trust signalCompliance4 records
Apo-Care Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Apo-Care Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Apo-Care Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Apo-Care Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Apo-Care Pharma
What does Apo-Care Pharma do?
Apo-Care Pharma GmbH manufactures and distributes specialty generic pharmaceuticals and medical devices in Germany. Its core offering is child-friendly liquid oral suspension formulations for oncology, hematology, immunology, and rare diseases (e.g., Xaluprine®, Xromi®, Qaialdo®, Jayempi®), supported by a GMP-certified production facility in Heidelberg. The company also distributes automated external defibrillators (AEDs) under the ResQ-Care brand as an exclusive partner of CU Medical Systems Inc.
Is Apo-Care Pharma a public or private company?
Apo-Care Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Apo-Care Pharma founded?
Apo-Care Pharma was founded in 1993. It employs 11 to 50 people.
Where is Apo-Care Pharma based?
Apo-Care Pharma is headquartered in Bielefeld, Germany, in the Europe region.
How does Apo-Care Pharma make money?
Three revenue lines are on record. Specialty Pharmaceutical Product Sales are the primary driver. The others are medical Wholesale Distribution and medical Device Distribution (AEDs).
Who are Apo-Care Pharma's main competitors?
Direct peers on record are STADA Arzneimittel AG, Hexal AG (Sandoz), Proveca Pharma, Mindray, Ethypharm, Phoenix Group, SERB Pharmaceuticals, ZOLL Medical Corporation and ratiopharm GmbH. Philips (HeartStart) is listed as a broad incumbent.
Does Apo-Care Pharma have an API?
No public API is recorded for Apo-Care Pharma.
What industry is Apo-Care Pharma in?
Apo-Care Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 42421 and its SIC code is 2834.